Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Good financial results growth rate 10.5% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (38.0%)
  • Dividend yield for the last twelve months 4.8%
  • Free cash flow yield -16.0% (LTM)
  • Share price is 25.1% higher than minimum and 38.9% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (2.8x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (+0.9%)49.595
year average price 49.13  


year start price 58.58 2023-09-18

max close price 59.16 2023-09-25

min close price 39.66 2024-07-05

current price 49.60 2024-09-16
Common stocks: 2 111 517 922

Dividend Yield:  4.8%
FCF Yield LTM: -16.0%
EV / LTM EBITDA: 2.8x
EV / EBITDA annualized: 3.5x
Last revenue growth (y/y):  +8.7%
Last growth of EBITDA (y/y):  +12.2%
Historical revenue growth:  +1.7%
Historical growth of EBITDA:  +74.3%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 104 721
Net Debt ($m): 46 150
EV (Enterprise Value): 150 871
EBITDA LTM ($m): 53 203
EV / LTM EBITDA: 2.8x
Price to Book: 6.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-09-16zacks.com

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

2024-09-15businesswire.com

Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma

2024-09-14fool.com

Got $200? 2 Healthcare Stocks to Buy and Hold Forever

2024-09-11zacks.com

Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

2024-09-09forbes.com

Bristol Myers Squibb Dividend Yield Pushes Past 5%

2024-09-08fool.com

2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100

2024-09-06seekingalpha.com

Bristol-Myers Squibb: A Better Earnings Outlook, Stronger Momentum Heading Into 2025

2024-09-06seekingalpha.com

Bristol-Myers Squibb Company (BMY) Wells Fargo 2024 Healthcare Conference (Transcript)

2024-09-06seekingalpha.com

Bristol-Myers Still A Value Play Despite Appreciating 26.56% From 2024 Lows

2024-09-05zacks.com

Bristol Myers Squibb (BMY) Falls More Steeply Than Broader Market: What Investors Need to Know
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data